175205-45-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Chlorobenzyl)-5-oxopyrrolidine-3-carboxylic acid is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to form various bioactive compounds. Its unique structure allows for the creation of molecules with potential therapeutic effects.
Used in Research Chemicals:
In the field of research, 1-(2-Chlorobenzyl)-5-oxopyrrolidine-3-carboxylic acid is used as a building block for the development of new chemical entities. Its versatility in chemical reactions makes it a valuable tool for medicinal chemists in exploring novel drug candidates.
Used in Medicinal Chemistry:
1-(2-Chlorobenzyl)-5-oxopyrrolidine-3-carboxylic acid is utilized as a structural component in the design and synthesis of new molecules with potential medicinal properties. Its presence in a compound can influence the pharmacokinetics and pharmacodynamics, contributing to the overall effectiveness of the drug.
Potential Use in Antibacterial and Antifungal Agents:
While further research is needed, 1-(2-Chlorobenzyl)-5-oxopyrrolidine-3-carboxylic acid may be used as an antibacterial or antifungal agent due to its chemical structure, which could interact with microbial cells and inhibit their growth.

InChI:InChI=1/C12H12ClNO3/c13-10-4-2-1-3-8(10)6-14-7-9(12(16)17)5-11(14)15/h1-4,9H,5-7H2,(H,16,17)

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 89-97-4 2-CHLOROBENZYLAMINE 

Relevant academic research and scientific papers

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives

A novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl}-1- methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), was identified as a CCR5 antagonist by high-throughput screening using [125I]RANTES and CCR5-expressing CHO cells. The IC50 value of 1 was 1.9 μM. In an effort to improve the binding affinity of 1, a series of 5-oxopyrrolidine-3- carboxamides was synthesized. Introduction of 3,4-dichloro substituents to the central phenyl ring (10i, IC50=0.057 μM; 11b, IC 50=0.050 μM) or replacing the 1-methyl group of the 5-oxopyrrolidine moiety with a 1-benzyl group (12e, IC50=0.038 μM) was found to be effective for improving CCR5 affinity. Compound 10i, 11b, and 12e also inhibited CCR5-using HIV-1 envelope-mediated membrane fusion with IC50 values of 0.44, 0.19, and 0.49 μM, respectively.

CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF

A compound of the formula: wherein R1 is a hydrocarbon group, R2 is a hydrocarbon group having 2 or more carbon atoms, where R1 and R2 may in combination form, together with an adjacent nitrogen atom, a ring optionally having a substituent or substituents, R3 is a hydrocarbon group optionally having a substituent or substituents or a heterocyclic group optionally having a substituent or substituents, R4 is a hydrogen atom, a hydrocarbon group, a heterocyclic group and the like, E is a divalent chain hydrocarbon group and the like, G is CO or SO2, J is a nitrogen atom, a methine group and the like, and Q and R are each a divalent chain C1-3 hydrocarbon group and the like, and a salt thereof show a superior CCR5 antagonistic activity and are useful as agents for the prophylaxis or treatment of HIV infection of human peripheral blood mononuclear cells, particularly AIDS.